New Horizons in Stage IV NSCLC: Key Takeaways from the 2026 ASCO Living Guideline Update

1. Introduction: The Evolution of "Living" Guidelines

The therapeutic landscape for Non–Small Cell Lung Cancer (NSCLC) is characterized by a rapid influx of clinical data that necessitates a more agile approach to evidence synthesis. To address this, ASCO maintains "Living Guidelines"—dynamic documents updated frequently to reflect the current state of science. This update (version 2026.3.1) focuses on systemic therapy for Stage IV NSCLC without driver alterations (EGFR, ALK, ROS1, etc.). While the overarching management paradigms remain stable, the inclusion of new PD-1 inhibitors, bispecific antibodies, and specialized regimens for intracranial disease provides clinicians with an expanded, though increasingly complex, toolkit for patient care.

2. The New Recommendation: Retifanlimab Plus Chemotherapy

The most notable addition to the first-line setting is retifanlimab, a PD-1 inhibitor. While the pivotal POD1UM-304 trial included both histologies, the ASCO Expert Panel has currently localized its recommendation specifically to nonsquamous cell carcinoma (Recommendations 1.8, 1.15, and 1.23).

Clinical Efficacy: POD1UM-304 Phase III Trial

The addition of retifanlimab to platinum-based chemotherapy demonstrated statistically significant improvements in survival and response compared to chemotherapy alone. However, the Panel notes "serious imprecision" in the data due to the reliance on a single study.

Metric	Retifanlimab + Chemotherapy	Placebo + Chemotherapy	Statistical Significance
Median Overall Survival (OS)	18.1 months	13.4 months	HR, 0.75 (95% CI, 0.60–0.93); P = .0042
Median Progression-Free Survival (PFS)	7.7 months	5.5 months	HR, 0.64 (95% CI, 0.52–0.79); P < .0001
Objective Response Rate (ORR)	52% (95% CI, 47–57)	39% (95% CI, 32–46)	P = .0012
Median Duration of Response	12.7 months	6.1 months	—

Safety and Adverse Events

Retifanlimab exhibited no new safety signals, though the investigational arm saw higher incidences of treatment-emergent adverse events (TEAEs). Common treatment-related adverse events (TRAEs) in the retifanlimab arm included:

• Anemia: 63% (Grade $\ge$ 3: 19%)
• Neutrophil count decrease: 22% (Grade $\ge$ 3: 14%)
• Decreased appetite: 23%
• Nausea: 21%
• Hyperthyroidism: 9%

Clinical Interpretation

The Expert Panel characterizes the retifanlimab data as a "class effect" of PD-1 inhibitors rather than a breakthrough in efficacy over established standards (e.g., pembrolizumab). The recommendation is conditional, intended primarily to expand treatment access in settings where cost and local availability are determining factors in therapeutic selection.

3. On the Horizon: Ivonescimab and Bispecific Innovation

One of the most promising areas of innovation involves ivonescimab, a PD-1/VEGF bispecific antibody. Data from the HARMONi-6 trial has positioned this agent as a significant candidate for future first-line use, particularly in squamous NSCLC.

HARMONi-6 Efficacy and Safety

In a trial of 532 Chinese patients with advanced squamous NSCLC, ivonescimab plus chemotherapy was compared against tislelizumab plus chemotherapy.

• Efficacy: Ivonescimab significantly improved median PFS (11.1 vs 6.9 months; HR, 0.60 [95% CI, 0.46–0.78]; P < .0001). Benefit was maintained across PD-L1 subgroups, including PD-L1 negative disease (PFS HR, 0.55).
• Safety: Grade $\ge$ 3 TRAEs were higher in the ivonescimab arm (64% vs 54%). Specific toxicities included alopecia (65%), anemia (53%), and neutropenia (45%). Grade $\ge$ 3 hemorrhage occurred in 2% of patients.

Watch This Space: Dual-Pathway Binding Ivonescimab utilizes a unique tetravalent structure designed to enable dual-pathway binding. By simultaneously targeting PD-1 and vascular endothelial growth factor (VEGF), the agent may overcome resistance mechanisms and improve outcomes across diverse PD-L1 expression levels.

A Measured Interpretation

While these results are clinically meaningful, the Expert Panel urges caution. The OS data is currently immature, and the trial was conducted exclusively in a Chinese population. Furthermore, the control arm had higher rates of brain metastases. Global validation is required; the ongoing HARMONi-3 trial comparing ivonescimab plus chemotherapy to pembrolizumab plus chemotherapy will be definitive.

4. Addressing Brain Metastases: The BAP BRAIN Trial

For patients with nonsquamous NSCLC and brain metastases, the BAP BRAIN trial evaluated the intracranial efficacy of adding bevacizumab (at a dose of 7.5 mg/kg) to a platinum-pemetrexed doublet.

Trial Criteria and Efficacy

The study enrolled patients with at least three brain lesions (unless local therapy was refused). The addition of bevacizumab resulted in:

• Intracranial PFS (iPFS): 11.07 vs 7.37 months (HR, 0.494 [95% CI, 0.343–0.712]; P < .001).
• Intracranial Response Rate (iORR): 69.9% vs 32.4% (OR, 4.77).
• Overall Survival: 28.07 vs 18.53 months (HR, 0.752 [95% CI, 0.505–1.122]).
• Safety: Participants in the bevacizumab arm experienced a 10% increase in Grade $\ge$ 3 AEs.

Clinical Caveats

This trial’s relevance is constrained by its design, as it was conducted in the pre-immunotherapy era. Consequently, this bevacizumab-containing regimen is not a replacement for current standards but may be considered for the specific subgroup of patients not eligible for immunotherapy who lack oncogenic drivers.

5. The Bedrock of Care: Biomarkers and Palliative Integration

Regardless of emerging agents, high-quality outcomes depend on comprehensive diagnostic workups and supportive care. The guideline emphasizes that molecular profiling should be exhaustive and early.

Checklist for Excellence

• Comprehensive Biomarker Testing (Recommendation 1.0): Universally accessible testing for all NSCLC patients using broad multigene panels.
• RNA-Based NGS: Preferred methodology to maximize the detection of genomic alterations (MET, HER2, etc.).
• PD-L1 IHC Limitations: Clinical teams are cautioned that PD-L1 IHC alone should not be used to guide treatment decisions; it must be interpreted alongside genomic data.
• Early Palliative Integration (Recommendation 3.1): Referral to interdisciplinary palliative care teams should occur early in the disease course, concurrently with active systemic therapy.

6. Conclusion: Navigating Treatment Selection

The 2026 ASCO Living Guideline Update (2026.3.1) confirms that while the core strategy for Stage IV NSCLC without driver alterations remains histology-based and PD-L1-driven, the therapeutic repertoire is expanding. The introduction of retifanlimab provides a new conditional option for nonsquamous disease, while bispecific antibodies like ivonescimab signal a potential shift in the treatment of squamous histology pending global validation.

Key Takeaways

1. Retifanlimab is a new conditional first-line option specifically recommended for nonsquamous histology, confirming a robust class effect for PD-1 inhibition.
2. Biomarker testing is non-negotiable; clinicians should prioritize broad RNA-based NGS panels and recognize the limitations of standalone PD-L1 IHC.
3. Intracranial efficacy can be enhanced with bevacizumab (7.5 mg/kg) in specific immunotherapy-ineligible populations with multiple brain lesions.
4. Bispecific antibodies are showing significant promise in squamous populations (PFS HR 0.60), though global data remains the missing link for broad adoption.

For the full list of recommendations and updated treatment algorithms, clinicians should visit the ASCO website at ascopubs.org/nsclc-non-da-living-guideline or cancer.org.